The Department of Pharmaceuticals (DoP) has rejected the review application filed by Sanofi-Synthelabo (India) Pvt. Ltd. against price fixation of “Amiodarone Injection – 50mg/ml” as it was found during examination that the ceiling price fixed by the NPPA is in accordance with the provisions of DPCO, 2013 and is in order.